Muranaka M, Nakajima K, Suzuki S
J Allergy Clin Immunol. 1981 May;67(5):350-6. doi: 10.1016/0091-6749(81)90079-8.
Three groups of adult patients with bronchial asthma were subjected to long-term chrysotherapy (gold therapy), immunotherapy, or symptomatic therapy. Five of 14 patients who were treated with repeated injections of gold salt entered a symptom-free state that continued for more than 3 yr without the use of any bronchodilators or corticosteroids. In the other groups, there were no patients who entered such a state of long-term remission during the treatment. A statistically significant decrease in the bronchial responsiveness to inhaled acetylcholine was also observed in patients who received chrysotherapy. In the other groups, there were no significant differences between the bronchial responsiveness to acetylcholine that was estimated before the treatment and that measured after long-term treatment. Long-term chrysotherapy in the asthmatic patients did not reduce their serum level of total IgE. Gold salt, which is generally accepted as an antirheumatic drug, has also been used as an antiasthmatic drug by some Japanese practitioners despite the absence of evidence to support the therapeutic effect of the drug on asthma; the results of the study provide more information on the treatment of bronchial asthma with gold therapy.
三组成年支气管哮喘患者分别接受了长期金疗法（金制剂治疗）、免疫疗法或对症治疗。14名接受重复金盐注射治疗的患者中有5名进入无症状状态，在未使用任何支气管扩张剂或皮质类固醇的情况下持续了3年以上。在其他组中，治疗期间没有患者进入这种长期缓解状态。接受金疗法的患者对吸入乙酰胆碱的支气管反应性也出现了统计学上的显著下降。在其他组中，治疗前评估的对乙酰胆碱的支气管反应性与长期治疗后测量的反应性之间没有显著差异。哮喘患者的长期金疗法并未降低其血清总IgE水平。金盐通常被认为是一种抗风湿药物，尽管缺乏该药物对哮喘治疗效果的证据，但一些日本医生也将其用作抗哮喘药物；该研究结果为金疗法治疗支气管哮喘提供了更多信息。
